Select a medication above to begin.
Inflectra (infliximab-dyyb)
infliximab
Black Box Warnings .
Serious Infection Risk
weigh tx benefit vs. risk in pts w/ chronic or recurrent infection; pulmonary and extrapulmonary tuberculosis (TB), invasive fungal infections, and other opportunistic infections incl. Legionella and Listeria observed; some infections have been fatal; most infections occur in combo w/ other immunosuppressants; evaluate for TB risk factors and screen for latent TB infection before and during infliximab tx; initiate anti-TB tx before infliximab tx; monitor for infection s/sx during and after infliximab tx; since active TB has developed in pts w/ negative tuberculin skin test, monitor all pts for active TB s/sx; since histoplasmosis may be present in pts w/ negative antigen and antibody tests, consider empiric antifungal tx in pts w/ severe systemic illness if at risk for invasive fungal infection; D/C infliximab tx if serious infection or sepsis occurs
Malignancy
lymphoma and other malignancies, some fatal, reported in children and adolescents treated w/ TNF blockers; post-marketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) reported mostly in Crohn dz or ulcerative colitis pts, mostly adolescent and young adult males receiving concomitant azathioprine or mercaptopurine; uncertain whether HSTCL related to TNF-blocker monotherapy or in combo w/ other immunosuppressants
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = infliximab-dyyb
Crohn dz
- [5 mg/kg/dose IV q8wk]
- Start: 5 mg/kg/dose IV x1 on wk 0, 2, 6; Info: for moderate-severe or fistulizing dz; consider D/C if no response by wk 14; may incr. maint. dose to 10 mg/kg/dose IV q8wk if initial response lost; weigh risk/benefit of reinduction tx if maintenance tx interrupted
ulcerative colitis, moderate-severe
- [5 mg/kg/dose IV q8wk]
- Start: 5 mg/kg/dose IV x1 on wk 0, 2, 6
rheumatoid arthritis, moderate-severe
- [3 mg/kg/dose IV q8wk]
- Start: 3 mg/kg/dose IV x1 on wk 0, 2, 6; Info: use w/ methotrexate; may incr. dose up to 10 mg/kg/dose IV q8wk or frequency up to q4wk if incomplete response; weigh risk/benefit of reinduction tx if maintenance tx interrupted
ankylosing spondylitis
- [5 mg/kg/dose IV q6wk]
- Start: 5 mg/kg/dose IV x1 on wk 0, 2, 6
psoriatic arthritis
- [5 mg/kg/dose IV q8wk]
- Start: 5 mg/kg/dose IV x1 on wk 0, 2, 6
psoriasis, severe chronic plaque
- [5 mg/kg/dose IV q8wk]
- Start: 5 mg/kg/dose IV x1 on wk 0, 2, 6; Info: if maintenance tx interrupted, restart 5 mg/kg/dose x1, then 5 mg/kg/dose IV q8wk
COVID-19 (off-label)
- [5 mg/kg/dose IV x1]
- Info: for hospitalized pts w/ severe COVID-19 requiring supplemental oxygen but not mechanical ventilation or extracorporeal membrane oxygenation (ECMO); not 1st-line agent
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = infliximab-dyyb
Crohn dz, moderate-severe
- [6 yo and older]
- Dose: 5 mg/kg/dose IV q8wk; Start: 5 mg/kg/dose IV x1 on wk 0, 2, 6; Info: weigh risk/benefit of reinduction tx if maintenance tx interrupted
ulcerative colitis, moderate-severe
- [6 yo and older]
- Dose: 5 mg/kg/dose IV q8wk; Start: 5 mg/kg/dose IV x1 on wk 0, 2, 6
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]